

8 August 2019

PolyNovo Limited
ABN 96 083 866 862

2/320 Lorimer Street
Port Melbourne
VIC Australia 3207

P +61 (0) 3 8681 4050
F +61 (0) 3 8681 4099

ASX Announcement

PolyNovo gains Singapore regulatory approval

PolyNovo is pleased to announce the successful registration of NovoSorb BTM with the Health Sciences Authority of Singapore.

Sales of NovoSorb BTM in Singapore will occur only after the appointment of a distributor.

PolyNovo will be attending and displaying at the Asian Burns Conference in Singapore 14-16 August and this will be an excellent forum to meet with key surgeons and distributors across the region.

PolyNovo is still awaiting CE certification.

CEO Paul Brennan said; *“Singapore is a small but key strategic market for our SE Asian success. We are excited about the prospects ahead with this approval coming at a good time for our attendance and display at the Asia Burns conference in Singapore next week.”*

Further information,

Paul Brennan
Chief Executive Officer
Mobile, +61 427 662 317

David Williams
Chairman
Mobile +61 414 383 593

About NovoSorb®

NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including, film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and programmable bio-resorption profile.

About PolyNovo®

PolyNovo is an Australian based medical device company that designs, develops and manufactures dermal regeneration solutions (NovoSorb BTM) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information and market presentations see www.polyново.com.au